Every Form 4 that Bluejay Diagnostics, Inc. (BJDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BJDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BJDX filings page.
Bluejay Diagnostics, Inc. (BJDX) reported that director Fred S. Zeidman received a grant of 100,000 stock options on 2026-08-17. These options have an exercise price of $2.075 per share and expire on 2031-08-17. They vest on the first anniversary of the grant date and are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Following this grant, Zeidman holds 100,000 options directly.
Bluejay Diagnostics, Inc. (BJDX) reported that director Wurth Douglas Clark received a grant of stock options for 100,000 shares of common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and are currently out-of-the-money. They vest on the first anniversary of the grant date and cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
Bluejay Diagnostics, Inc. (BJDX) reported that director Svetlana Dey received a grant of 100,000 stock options to purchase common stock at an exercise price of $2.075 per share. The options vest and become exercisable on the first anniversary of the grant, but cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. These options expire on August 17, 2031, and following this grant Dey holds 100,000 options directly.
Bluejay Diagnostics, Inc. (symbol: BJDX) is the issuer of record for a Form 4 filing submitted to the SEC.
Bluejay Diagnostics, Inc. (BJDX) reported that director Donald R. Chase received a grant of 100,000 stock options to purchase common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and vest on the first anniversary of the grant date. According to the award terms, the options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
Bank of America Corporation, Bank of America N.A. and BofA Securities, Inc. jointly state that their beneficial ownership in Bluejay Diagnostics, Inc. has fallen below 10 percent, so they are no longer treated as Section 16 ten percent owners.
HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc., reported mixed trading in the company’s common stock. On July 9, 2026, it executed an open-market purchase of 64,047 shares at $1.51 per share. On July 10, 2026, it made an open-market sale of 34,938 shares at $1.40 per share. After these transactions, HRT Financial LP directly held 92,055 shares of Bluejay Diagnostics common stock, reflecting a net increase of 29,109 shares over the two days.
Bluejay Diagnostics, Inc. received a Form 4 filing from three related institutional holders: BANK OF AMERICA CORP /DE/, BOFA SECURITIES, INC., and BANK OF AMERICA NA. Each is identified as a ten percent owner of Bluejay Diagnostics, but this filing does not list any specific share transactions or option exercises, functioning instead as a beneficial ownership report.
Bluejay Diagnostics director Wurth Douglas Clark bought additional common stock in the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock from the issuer in a private placement at $2.00 per share.
Following this transaction, his reported holdings increased to 12,608 shares of common stock, which includes 34 shares held by Wurth Holdings LLC, an entity he controls.
Bluejay Diagnostics, Inc. director and President/CEO Indranil Dey bought additional company stock. On March 14, 2026, he purchased 12,500 shares of common stock from the company in a private placement at $2.00 per share, bringing his direct holdings to 12,522 shares. He also indirectly owns 127 shares held by Lana Management & Business Research International, LLC, over which he has voting and dispositive power.
Bluejay Diagnostics director Donald R. Chase increased his stake by buying shares directly from the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement at $2.00 per share, a total investment of $25,000. After this transaction, he directly owns 12,525 common shares of the company.
Bluejay Diagnostics director Fred S. Zeidman bought additional shares of the company’s stock. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share. Following this transaction, he directly owns 12,500 common shares.
Bluejay Diagnostics director Svetlana Dey bought additional company stock. On March 14, 2026, she purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share.
After this transaction, Ms. Dey directly owns 12,501 common shares and indirectly controls 127 common shares held through Lana Management & Business Research International, LLC, over which she has voting and dispositive power.